🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Efficacy and Safety of Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis

RecruitingPhase 3Ages 16 Years - anyAllSint Maartenskliniek
NCT07371572 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to determine the efficacy and safety of intramuscular methylprednisolone in patients with hand osteoarthritis. The main question it aims to answer is what the difference is in hand pain 4 weeks after the first injection with methylplrednisolone. This main goal will be assessed in the first 16 weeks, the RCT phase. Researchers will compare 120mg methylprednisolone with 40mg methylprednisolone and placebo to see if there is a difference in hand pain after 4 weeks. Participants will be asked to visit the hospital for: * injection of the study material * ultrasound assessment * physical examination like joint assessments and grip strenght * examination of blood * x-ray of the hand In phase 2, from week 16 to 48, an open label phase focusing on treatment strategy and safety. In this phase all participants may receive intramuscular methylprednisolone on de

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with interphalangeal hand OA (according to the EULAR classification criteria 2023) based on patient report (age, morning stiffness) and radiographs of ≤6 months old (osteophytes, JSN (joint space narrowing) and symptom-structure concordance (present if majority (≥50%) of the symptomatic joints demonstrate radiographic findings)). * Age ≥ 16 years * Have hand pain \>40mm on a 100mm visual analogue scale (VAS) * Have previously experienced failure of at least one conventional type of pain medication, (self-reported of insufficient effect from topical or oral NSAID, etc. with exclusion of paracetamol) Exclusion Criteria: * Comorbidity * Chronic inflammatory (rheumatic) diseases * Infectious diseases * Known Osteoporosis * Known Diabetes * Previous diagnosis of fibromyalgia * Known myasthenia gravis * Previous surgical interventions on the hand (e.g. carpal tunnel syndrome, etc.) * Use of other Medication: In order to maximize the generalizability of the study interactions between methylprednisolone and co-medication is only prohibited when the Dutch Medication Surveillance System (Z-index) gives a signal for this interaction. * Patients with a contraindication for MP * Current Gastric and duodenal ulcers * Current infections * Liver cirrhosis * Pregnant or breastfeeding * Known non-response or intolerance for MP * Not able to read or write the Dutch language * Neurological diagnosis * Epilepsy * Risk of psychiatric disorder
💊

What it tests

  • 120mg methylprednisolone acetate
  • 40mg methylprednisolone acetate
  • Placebo
📍

Where

1 site
Sint Maartenskliniek
Ubbergen, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy